CN105092858A - 借助抗利尿激素原对呼吸道和肺部的感染及慢性病的诊断和风险性分级 - Google Patents
借助抗利尿激素原对呼吸道和肺部的感染及慢性病的诊断和风险性分级 Download PDFInfo
- Publication number
- CN105092858A CN105092858A CN201510454116.7A CN201510454116A CN105092858A CN 105092858 A CN105092858 A CN 105092858A CN 201510454116 A CN201510454116 A CN 201510454116A CN 105092858 A CN105092858 A CN 105092858A
- Authority
- CN
- China
- Prior art keywords
- purposes according
- disease
- proavp
- mark
- respiratory tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 37
- 208000015181 infectious disease Diseases 0.000 description 31
- 210000002345 respiratory system Anatomy 0.000 description 31
- 208000017667 Chronic Disease Diseases 0.000 description 29
- 210000004072 lung Anatomy 0.000 description 26
- 108010004977 Vasopressins Proteins 0.000 description 23
- 102000002852 Vasopressins Human genes 0.000 description 23
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 23
- 229960003726 vasopressin Drugs 0.000 description 23
- 208000019693 Lung disease Diseases 0.000 description 20
- 238000003745 diagnosis Methods 0.000 description 20
- 239000012634 fragment Substances 0.000 description 20
- 108010048233 Procalcitonin Proteins 0.000 description 19
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 108010064409 proAVP hormone Proteins 0.000 description 12
- 206010035664 Pneumonia Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 230000002685 pulmonary effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 206010057190 Respiratory tract infections Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000000414 obstructive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000009798 acute exacerbation Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010061736 Bronchitis bacterial Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010202 multivariate logistic regression analysis Methods 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006053442A DE102006053442A1 (de) | 2006-11-12 | 2006-11-12 | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| DE102006053442.5 | 2006-11-12 | ||
| CNA2007800420148A CN101563613A (zh) | 2006-11-12 | 2007-11-11 | 借助抗利尿激素原、特别是和肽素或ⅱ型后叶激素运载蛋白对呼吸道和肺部的感染及慢性病的诊断和风险性分级 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800420148A Division CN101563613A (zh) | 2006-11-12 | 2007-11-11 | 借助抗利尿激素原、特别是和肽素或ⅱ型后叶激素运载蛋白对呼吸道和肺部的感染及慢性病的诊断和风险性分级 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105092858A true CN105092858A (zh) | 2015-11-25 |
Family
ID=39277664
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800420148A Pending CN101563613A (zh) | 2006-11-12 | 2007-11-11 | 借助抗利尿激素原、特别是和肽素或ⅱ型后叶激素运载蛋白对呼吸道和肺部的感染及慢性病的诊断和风险性分级 |
| CN201510454116.7A Pending CN105092858A (zh) | 2006-11-12 | 2007-11-11 | 借助抗利尿激素原对呼吸道和肺部的感染及慢性病的诊断和风险性分级 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800420148A Pending CN101563613A (zh) | 2006-11-12 | 2007-11-11 | 借助抗利尿激素原、特别是和肽素或ⅱ型后叶激素运载蛋白对呼吸道和肺部的感染及慢性病的诊断和风险性分级 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8158368B2 (enExample) |
| EP (2) | EP2089718B1 (enExample) |
| JP (3) | JP5340160B2 (enExample) |
| CN (2) | CN101563613A (enExample) |
| AT (1) | ATE522814T1 (enExample) |
| DE (1) | DE102006053442A1 (enExample) |
| DK (1) | DK2378290T3 (enExample) |
| ES (2) | ES2634137T3 (enExample) |
| HK (1) | HK1215731A1 (enExample) |
| WO (1) | WO2008058517A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140046407A1 (en) * | 2001-08-31 | 2014-02-13 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| DE112007003185A5 (de) * | 2006-10-26 | 2009-10-01 | Brahms Aktiengesellschaft | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II |
| DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| WO2011044142A1 (en) * | 2009-10-05 | 2011-04-14 | Duke University | Peripheral blood biomarkers for idiopathic interstitial pneumonia and methods of use |
| EP2776064A4 (en) | 2011-11-11 | 2015-08-05 | Woomera Therapeutics | ANTAGONISTS OF PRO-VASOPRESSIN AND USES THEREOF |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| KR102511128B1 (ko) | 2022-03-31 | 2023-03-16 | (주)네오닉스 | 배터리팩 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227454C1 (de) | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
| DE19600875C1 (de) * | 1996-01-12 | 1997-06-26 | Brahms Diagnostica Gmbh | Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse |
| DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| ATE356874T1 (de) | 1999-12-22 | 2007-04-15 | Dade Behring Marburg Gmbh | Lösungen von humanem procalcitonin |
| DE10027954A1 (de) | 1999-12-22 | 2001-06-28 | Dade Behring Marburg Gmbh | Humanes Procalcitonin, dessen Herstellung und Verwendung |
| MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
| WO2004006860A2 (en) * | 2002-07-16 | 2004-01-22 | Woomera Therapeutics, Inc. | Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
| JP2006526140A (ja) * | 2002-12-24 | 2006-11-16 | バイオサイト インコーポレイテッド | 鑑別診断のためのマーカーおよびその使用方法 |
| GB0401730D0 (en) * | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
| EP1628136A1 (en) | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102004047968A1 (de) * | 2004-10-01 | 2006-04-06 | B.R.A.H.M.S Ag | Bestimmung von Gastrokine 1 (GKN1) als Biomarker für Entzündungen und Infektionen |
| GB0508863D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Peptide |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| JP4983525B2 (ja) * | 2007-10-11 | 2012-07-25 | 住友電装株式会社 | ワイヤハーネスのプロテクタ取付構造 |
| DK2427764T3 (en) * | 2009-05-05 | 2017-09-11 | Brahms Gmbh | VASOACTIVE HORMON-BASED STRATIFICATION OF PATIENTS SUFFERING OF DISEASES RELATED TO ENDOTELIAL FUNCTION / DYSFUNCTION |
-
2006
- 2006-11-12 DE DE102006053442A patent/DE102006053442A1/de not_active Withdrawn
-
2007
- 2007-11-11 DK DK11170807.9T patent/DK2378290T3/en active
- 2007-11-11 US US12/514,524 patent/US8158368B2/en active Active
- 2007-11-11 ES ES11170807.9T patent/ES2634137T3/es active Active
- 2007-11-11 EP EP07846321A patent/EP2089718B1/de active Active
- 2007-11-11 EP EP11170807.9A patent/EP2378290B1/de active Active
- 2007-11-11 AT AT07846321T patent/ATE522814T1/de active
- 2007-11-11 JP JP2009535559A patent/JP5340160B2/ja active Active
- 2007-11-11 CN CNA2007800420148A patent/CN101563613A/zh active Pending
- 2007-11-11 WO PCT/DE2007/002037 patent/WO2008058517A2/de not_active Ceased
- 2007-11-11 CN CN201510454116.7A patent/CN105092858A/zh active Pending
- 2007-11-11 ES ES07846321T patent/ES2370071T3/es active Active
-
2012
- 2012-03-21 US US13/425,928 patent/US20120270245A1/en not_active Abandoned
-
2013
- 2013-01-04 JP JP2013000176A patent/JP2013083664A/ja active Pending
-
2015
- 2015-07-31 JP JP2015151852A patent/JP6170101B2/ja active Active
-
2016
- 2016-03-30 HK HK16103639.3A patent/HK1215731A1/zh unknown
- 2016-06-13 US US15/180,797 patent/US10718783B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ATE522814T1 (de) | 2011-09-15 |
| US8158368B2 (en) | 2012-04-17 |
| EP2378290A1 (de) | 2011-10-19 |
| WO2008058517A2 (de) | 2008-05-22 |
| EP2089718A2 (de) | 2009-08-19 |
| US20100041064A1 (en) | 2010-02-18 |
| EP2089718B1 (de) | 2011-08-31 |
| US20170059583A1 (en) | 2017-03-02 |
| JP6170101B2 (ja) | 2017-07-26 |
| EP2378290B1 (de) | 2017-05-03 |
| HK1215731A1 (zh) | 2016-09-09 |
| ES2634137T3 (es) | 2017-09-26 |
| JP2013083664A (ja) | 2013-05-09 |
| JP2010509576A (ja) | 2010-03-25 |
| US20120270245A1 (en) | 2012-10-25 |
| DK2378290T3 (en) | 2017-07-31 |
| JP2016026286A (ja) | 2016-02-12 |
| US10718783B2 (en) | 2020-07-21 |
| ES2370071T3 (es) | 2011-12-12 |
| JP5340160B2 (ja) | 2013-11-13 |
| DE102006053442A1 (de) | 2008-05-15 |
| CN101563613A (zh) | 2009-10-21 |
| WO2008058517A3 (de) | 2008-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105092858A (zh) | 借助抗利尿激素原对呼吸道和肺部的感染及慢性病的诊断和风险性分级 | |
| Wang et al. | Epidemiology and outcomes of acute kidney injury in COVID-19 patients with acute respiratory distress syndrome: a multicenter retrospective study | |
| JP5663531B2 (ja) | 心不全を伴う気道および肺の感染または炎症性疾患の診断 | |
| Simcock et al. | Proangiogenic activity in bronchoalveolar lavage fluid from patients with asthma | |
| JP5185460B2 (ja) | ｉｎｖｉｔｒｏプロカルシトニン・アッセイ方法 | |
| ES2388055T3 (es) | Diagnóstico y estratificación de riesgo mediante NT-proET-1 | |
| CN102782501A (zh) | 在无症状患者中基于il-6检测的全身炎性应答综合征和败血症的早期诊断和预测 | |
| JPWO2007136026A1 (ja) | 抗原タンパク質の定量方法及び定量用キット | |
| JP2010509576A5 (enExample) | ||
| JP2022553420A (ja) | 敗血症管理 | |
| Gille et al. | Evaluation of MR-proANP and copeptin for sepsis diagnosis after burn injury | |
| Campbell et al. | The negative acute phase response of serum transthyretin following Streptococcus suis infection in the pig | |
| CN111051888B (zh) | 真菌感染的诊断和风险分层 | |
| CN113514643A (zh) | 剪接相关蛋白130用于特发性肺间质纤维化诊断和疾病严重程度评估 | |
| Crowley et al. | Noninvasive, multiOmic, and Multicompartmental Biomarkers of Reflux Disease: A Systematic Review | |
| CN115586341A (zh) | 尿液外泌体蛋白作为病毒性肺炎诊断标志物的应用 | |
| HK1137807B (en) | Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure | |
| Carretta | MO143UTILITY of Sift-MS to Evaluate Volatile Organic Compounds in Nephropathic Patients' Breath | |
| HK1135183A (en) | Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin ii | |
| WO2022091793A1 (ja) | 糞便由来タンパク質を用いた膵臓がんバイオマーカーの開発 | |
| Dunne et al. | 5.3 Potential role for intestinal myofibroblasts in coeliac | |
| HK1177963B (en) | Il-6 detection based early diagnosis and prediction of systemic inflammatory response syndrome and sepsis in asymptomatic patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1215731 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151125 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1215731 Country of ref document: HK |